

Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight

DelveInsight's Migraine Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES,

May 22, 2024 /EINPresswire.com/ --

The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.



DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Migraine Market Forecast](#)

Some of the key facts of the Migraine Market Report:

The Migraine market size was valued approximately USD 8,985 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

The United States holds the dominant share in the migraine market, with a market size of around USD 5,715 million in 2022, projected to rise by 2032.

In 2022, the collective market size for migraine in the European Union Four (EU4) countries and the United Kingdom amounted to USD 2,693 million. This market is expected to experience substantial growth at a significant Compound Annual Growth Rate (CAGR).

In 2022, the collective number of existing cases of Migraine across the 7MM (Seven Major Markets) stood at 118,860,221. This figure is anticipated to experience significant growth at a

substantial Compound Annual Growth Rate (CAGR) over the research duration spanning from 2019 to 2032.

The United States holds the highest number of prevalent Migraine cases among the Seven Major Markets (7MM), totaling 45,820,557 cases. This figure is projected to escalate sharply in the near future, primarily attributed to advancements in diagnostic testing methods and the growing population.

In Europe, Germany recorded the highest prevalent Migraine population, totaling 12,579,243 cases, followed closely by Italy with 12,238,489 cases in 2022. Conversely, Spain had the lowest prevalent Migraine population among the Seven Major Markets (7MM), with 9,365,966 cases reported in the same year.

DelveInsight's analysts have categorized migraine cases based on severity into two types: episodic migraine and chronic migraine. In 2022, the number of cases for episodic migraine and chronic migraine stood at 111,370,558 and 7,489,664, respectively, across the Seven Major Markets (7MM).

Key Migraine Companies: Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

Key Migraine Therapies: AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKCRx (ISIS 546254), and others

The Migraine epidemiology based on gender analyzed that females experience a more significant impact in relation to Migraine compared to males

The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

Migraine Overview

Migraine, a main headache illness, is a neurological condition that commonly manifests as severe, incapacitating headaches among other symptoms. It affects all ages and frequently runs in families. There are primarily two types: acute migraine and Migraine.

Get a Free sample for the Migraine Market Report

https://www.delveinsight.com/report-store/migraine-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Migraine Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Migraine Epidemiology Segmentation:

The Migraine market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Migraine

Prevalent Cases of Migraine by severity

Gender-specific Prevalence of Migraine

Diagnosed Cases of Episodic and Chronic Migraine

Download the report to understand which factors are driving Migraine epidemiology trends @ [Migraine Epidemiology Forecast](#)

Migraine Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Migraine Therapies and Key Companies

AXS-07: Axsome Therapeutics

ABP-450: AEON Biopharma, Inc.

Aimovig: Amgen

CL-H1T: Charleston Laboratories

AIMOVIG: Amgen

Fremanezumab: Teva Pharmaceuticals

Galcanezumab: Eli Lilly and Company

propranolol LA: Anne Lindblad

Atogepant: Allergan

LBR-101: Teva Branded Pharmaceutical

Atogepant: AbbVie

Galcanezumab: Eli Lilly and Company

Marcaine: Tian Medical Inc.

Atogepant: Allergan

Galcanezumab: Eli Lilly and Company

Eptinezumab: H. Lundbeck A/S

TNX-1900: Tonix Pharmaceuticals, Inc.

IONIS-PKCRx (ISIS 546254): Ionis Pharmaceuticals, Inc.

Scope of the Migraine Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Migraine Companies: Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

Key Migraine Therapies: AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKRx (ISIS 546254), and others

Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies

Migraine Market Dynamics: Migraine market drivers and Migraine market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Migraine Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement

To know more about Migraine companies working in the treatment market, visit @ [Migraine Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Migraine Market Report Introduction
2. Executive Summary for Migraine
3. SWOT analysis of Migraine
4. Migraine Patient Share (%) Overview at a Glance
5. Migraine Market Overview at a Glance
6. Migraine Disease Background and Overview
7. Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Migraine
9. Migraine Current Treatment and Medical Practices
10. Migraine Unmet Needs
11. Migraine Emerging Therapies
12. Migraine Market Outlook
13. Country-Wise Migraine Market Analysis (2019–2032)
14. Migraine Market Access and Reimbursement of Therapies
15. Migraine Market Drivers
16. Migraine Market Barriers
17. Migraine Appendix
18. Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 4699457679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/713788382>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.